Knight Therapeutics Reports Second Quarter 2026 Results
Increased 2026 guidance and expect revenues of $540 million to $560 million Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.